Drug Profile

Caxmotabart Entudotin - Iksuda Therapeutics/Shanghai Fosun Pharmaceutical

Alternative Names: FS-1502; IKS-014; LCB-14; LCB14-0110; Trastuzumab mafodotin; Trastuzumab-DAR 2 MMAF; Trastuzumab-monomethyl auristatin F

Latest Information Update: 05 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LegoChem Biosciences
Developer Iksuda Therapeutics; LigaChem Biosciences; Shanghai Fosun Pharmaceutical
Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Phase III Breast cancer; HER2 positive breast cancer
Phase II Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
No development reported Oesophageal cancer; Urogenital cancer

21 Mar 2025 Caxmotabart Entudotin - Iksuda Therapeutics/Shanghai Fosun Pharmaceutical is available for licensing as of 21 Mar 2025
28 Feb 2025 No recent reports of development identified for clinical-Phase-Unknown development in Oesophageal-cancer in South Korea (Parenteral)
28 Feb 2025 No recent reports of development identified for clinical-Phase-Unknown development in Urogenital-cancer in South Korea (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com